Oncolytics Biotech

Oncolytics Biotech reports promising BRACELET-1 results in HR+/HER2- metastatic breast cancer, setting stage for potential registration-enabling study and accelerated approval. The company also highlights advancements in its gastrointestinal cancer pipeline, with collaborations for pancreatic cancer studies. Anticipated milestones include finalizing protocols and safety data in 2025.

Oncolytics Biotech reports DSMB recommendation for continued enrollment in GOBLET study Cohort 5, assessing pelareorep with modified FOLFIRINOX and atezolizumab for pancreatic ductal adenocarcinoma, pending PEI approval. Safety data expected in H1 2025, with initial efficacy results in H2.

Oncolytics Biotech® Inc. will host a conference call and webcast on Nov 12, 2024, at 8:30 a.m. ET to discuss Q3 2024 financial results and recent operational highlights.

Oncolytics Biotech seeks accelerated approval for pelareorep, its lead cancer therapy, based on positive Phase II BRACELET-1 trial data. A registrational Phase II trial is planned for 2025, evaluating pelareorep combined with paclitaxel in breast cancer patients. Oncolytics' stock rose 18.22% on the news, reflecting investor optimism. Oncolytic virus therapies are projected to see significant growth, from $114m in 2023 to $2.4bn by 2029.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account typically reactivates within 24 hours; contact support if still disabled.